CytoSorbents Receives Full FDA Approval of Investigational Device Exemption For U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery
CytoSorbents Corporation (NASDAQ:CTSO) announces the full approval of its Investigational Device Exemption (IDE) application to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal – Ticagrelor)